Abacavir and cardiovascular disease: A critical look at the data

Antiviral Research

Volumn 132, Issue , 2016, Pages 116-121

  Llibre, Josep M ^a,b   Hill, Andrew ^c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Abacavir; Cardiovascular risk; Cohort studies; Myocardial infarction

Indexed keywords

ABACAVIR; TENOFOVIR; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACUTE HEART INFARCTION; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CD4 LYMPHOCYTE COUNT; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRESCRIPTION; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; CLINICAL TRIAL (TOPIC); COMPLICATION; HEART INFARCTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; META ANALYSIS (TOPIC); RISK;

ANTI-HIV AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIDEOXYNUCLEOSIDES; HIV INFECTIONS; HUMANS; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; RISK;

EID: 84973597932     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2016.05.015     Document Type: Review

References (37)

1. J.V. Baker, W.K. Henry, P. Patel, T.J. Bush, L.J. Conley, W.J. Mack, and et al. Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort Clin. Infect. Dis. 53 8 2011 826 835
2. P.D. Baum, P.M. Sullam, C.A. Stoddart, and J.M. McCune Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase AIDS 25 18 2011 2243 2248
3. C. Bavinger, E. Bendavid, K. Niehaus, R.A. Olshen, I. Olkin, V. Sundaram, and et al. Risk of cardiovascular disease from antiretroviral therapy for HIV: a systematic review PLoS One 8 3 2013 e59551
4. R.J. Bedimo, A.O. Westfall, H. Drechsler, G. Vidiella, and P. Tebas Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era Clin. Infect. Dis. 53 1 2011 84 91
5. C.H. Brothers, J.E. Hernandez, A.G. Cutrell, L. Curtis, M. Ait-Khaled, S.J. Bowlin, and et al. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects J. Acquir Immune Defic. Syndr. 51 1 2009 20 28
6. K.M. Chan-Tack, K.A. Struble, N. Morgensztejn, J.S. Murray, R. Gulick, B. Cheng, and et al. HIV clinical trial design for antiretroviral development: moving forward AIDS 22 18 2008 2419 2427
7. A.I. Choi, E. Vittinghoff, S.G. Deeks, C.C. Weekley, Y. Li, and M.G. Shlipak Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons AIDS 25 10 2011 1289 1298
8. D. Costagliola, S. Lang, M. Mary-Krause, and F. Boccara Abacavir and cardiovascular risk: reviewing the evidence Curr. HIV/AIDS Rep. 7 3 2010 127 133
9. M. Cruciani, V. Zanichelli, G. Serpelloni, O. Bosco, M. Malena, R. Mazzi, and et al. Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data AIDS 25 16 2011 1993 2004
10. M. Desai, V. Joyce, E. Bendavid, R.A. Olshen, M. Hlatky, A. Chow, and et al. Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population Clin. Infect. Dis. 61 3 2015 445 452
11. X. Ding, E. Andraca-Carrera, C. Cooper, P. Miele, C. Kornegay, M. Soukup, and et al. No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis J. Acquir Immune Defic. Syndr. 61 4 2012 441 447
12. M. Durand, O. Sheehy, J.G. Baril, J. LeLorier, and C.L. Tremblay Association between HIV infection, antiretroviral therapy, and risk of acute myocardial infarction: a cohort and nested case-control study using Quebec's public health insurance database J. Acquir Immune Defic. Syndr. 57 3 2011 245 253
13. M. Emerson, E. Smyth, and M. Nelson Cardiovascular risk profile of abacavir and tenofovir independent of HIV infection Boston, MA, 22-25 February 23TH Conference on Retroviruses and Opportunistic Infections (CROI) 2016 Abstract 662
14. E. George, G. Lucas, G. Nadkarni, D. Fine, R. Moore, and M. Atta Kidney function and the risk of cardiovascular events in HIV-1-infected patients AIDS 24 2010 387 394
15. S. Grinspoon, and A. Carr Cardiovascular risk and body-fat abnormalities in HIV-infected adults N. Engl. J. Med. 352 1 2005 48 62
16. A. Hill The environment and disease: association or causation? Proceed Roy. Soc. Med. - Lond. 58 1965 295 300
17. P.Y. Hsue, P.W. Hunt, Y. Wu, A. Schnell, J.E. Ho, H. Hatano, and et al. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients AIDS 23 15 2009 2021 2027
18. D.B. Klein, W.A. Leyden, L. Xu, C.R. Chao, M.A. Horberg, W.J. Towner, and et al. Declining relative risk for myocardial infarction among HIV-positive compared with HIV-negative individuals with access to care Clin. Infect. Dis. 60 8 2015 1278 1280
19. S. Lang, M. Mary-Krause, L. Cotte, J. Gilquin, M. Partisani, A. Simon, and et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4 Arch. Intern Med. 170 14 2010 1228 1238
20. J.L. Marcus, R.S. Neugebauer, W.A. Leyden, C.R. Chao, L. Xu, C.P. Quesenberry Jr., and et al. Use of abacavir and risk of cardiovascular disease among HIV-infected individuals J. Acquir Immune Defic. Syndr. 71 4 2016 413 419
21. A. Martin, M. Bloch, J. Amin, D. Baker, D.A. Cooper, S. Emery, and et al. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial Clin. Infect. Dis. 49 10 2009 1591 1601
22. A. Martin, J. Amin, D.A. Cooper, A. Carr, A.D. Kelleher, M. Bloch, and et al. Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial AIDS 24 17 2010 2657 2663
23. R. Martin-Iguacel, J. Llibre, and N. Friis-Moller Risk of cardiovascular disease in an aging HIV population: where are we now? Curr. HIV/AIDS Rep. 12 4 2015 375 387
24. N. Obel, D.K. Farkas, G. Kronborg, C.S. Larsen, G. Pedersen, A. Riis, and et al. Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study HIV Med. 11 2 2010 130 136
25. F. Palella, K. Althoff, J. Zhang, S. ange, R. Moore, M. Kitahata, and et al. Abacavir use and risk for myocardial infarction in the NA-ACCORD CROI 2015 February 23-26, 2015 | Seattle, Washington #749LB
26. H.J. Ribaudo, C.A. Benson, Y. Zheng, S.L. Koletar, A.C. Collier, J.J. Lok, and et al. No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT Clin. Infect. Dis. 52 7 2011 929 940
27. M. Rotger, T.R. Glass, T. Junier, J. Lundgren, J.D. Neaton, E.S. Poloni, and et al. Contribution of genetic background, traditional risk factors, and HIV-related factors to coronary artery disease events in HIV-positive persons Clin. Infect. Dis. 57 1 2013 112 121
28. C.A. Sabin, S.W. Worm, R. Weber, P. Reiss, W. El-Sadr, F. Dabis, and et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D: a:D study: a multi-cohort collaboration Lancet 371 9622 2008 1417 1426
29. C.A. Sabin, P. Reiss, L. Ryom, A.N. Phillips, R. Weber, M. Law, and et al. Is there continued evidence for an association between abacavir usage and myocardial infarction risk in individuals with HIV? A cohort collaboration BMC Med. 14 1 2016 61
30. C. Sabin, L. Lyom, A. d'Arminio Monforte, C. Hatleberg, C. Pradier, O. Kirk, and et al. Abacavir (ABC) use and risk of recurrent myocardial infarction (MI) Boston, MA, 22-25 February 23TH Conference on Retroviruses and Opportunistic Infections (CROI) 2016 Abstract 661
31. C.S. Satchell, J.A. O'Halloran, A.G. Cotter, A.J. Peace, E.F. O'Connor, A.F. Tedesco, and et al. Increased platelet reactivity in HIV-1-infected patients receiving abacavir-containing antiretroviral therapy J. Infect. Dis. 204 8 2011 1202 1210
32. P. Sax, D. Wohl, M. Yin, F. Post, E. deJesus, M. Saag, and et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials Lancet 2015 2606 2615
33. V.A. Triant, S. Regan, H. Lee, P.E. Sax, J.B. Meigs, and S.K. Grinspoon Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system J. Acquir Immune Defic. Syndr. 55 5 2010 615 619
34. Triumeq. Highlights of prescribing information. US Food and Drug Administration. Available at: http://www.fda.gov/default.htm. Accessed: April 6, 2016.
35. Triumeq. Summary of product characteristics. European Medicines Agency. Available at: http://www.ema.europa.eu/ema/. Accessed April 6, 2016.
36. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22(14):F17-F24.
37. J. Young, Y. Xiao, E.E. Moodie, M. Abrahamowicz, M.B. Klein, E. Bernasconi, and et al. The effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the Swiss HIV Cohort Study J. Acquir Immune Defic. Syndr. 2015